Latest Regulatory Approvals News

Mont Royal Resources is progressing its merger with Commerce Resources to create a dual-listed Canadian critical metals developer, combining rare earth and lithium assets in Quebec.

Caravel Minerals has secured a $15 million non-dilutive loan facility to fund the Definitive Feasibility Study for its Caravel Copper Project, alongside finalising a simplified process flowsheet and initiating key engineering tenders.

DMC Mining’s planned acquisition of the Firawa and Labé uranium projects in Guinea faces delays due to exploration license approvals, while the company’s cash reserves dwindle to just A$14,000.

Environmental Clean Technologies Limited has secured crucial regulatory approvals for its Bacchus Marsh fertiliser facility and completed a $275K capital raise, while deferring field trials to better align with cropping cycles. The company is also undergoing significant restructuring to improve capital efficiency and focus on strategic growth.

Uscom Limited reported a significant revenue decline in Q4 2025 amid global market instability but is focusing on cost management and strategic partnerships to position for recovery.

ReNerve Limited reported a robust 53% increase in annual revenue, driven by strategic partnerships and new regulatory approvals that broaden its global footprint in nerve repair.

The Star Entertainment Group reported steady Q4 FY25 revenue of $270 million but widened its EBITDA loss to $27 million, reflecting ongoing regulatory pressures and operational challenges. The company secured $233 million from strategic investors Bally’s Corporation and Investment Holdings, while negotiations continue over its Brisbane joint venture exit.

Nickel Industries reported record ore sales and EBITDA at its Hengjaya Mine for the June 2025 quarter, alongside significant progress on key projects and sustainability initiatives.

Arizona Lithium has secured regulatory approval for Phase 1 production at its Prairie Lithium Project in Saskatchewan and raised $4.25 million through an oversubscribed share purchase plan, marking key milestones toward commercial lithium extraction.

Cynata Therapeutics is advancing three pivotal clinical trials targeting acute Graft versus Host Disease, osteoarthritis, and kidney transplantation, with major results expected through early 2026. The company maintains a solid cash position supporting its clinical pipeline and strategic growth.

CurveBeam AI reported a solid 18% increase in purchase orders for FY25, alongside record cash receipts and positive operational cash flow in Q4. The company is also advancing a significant vendor financing facility to support growth in key markets.

Prescient Therapeutics has secured FDA Fast Track designation for PTX-100 in treating relapsed Cutaneous T-Cell Lymphoma and dosed the first patient in its Phase 2a trial, supported by a recent $6.8 million capital raise.